STOCK TITAN
  1. Home
  2. News
  3. CLSD

Clearside Biomedical, Inc. - CLSD STOCK NEWS

Welcome to our dedicated page for Clearside Biomedical news (Ticker: CLSD), a resource for investors and traders seeking the latest updates and insights on Clearside Biomedical stock.

Clearside Biomedical, Inc. (symbol: CLSD) is a prominent clinical biopharmaceutical company based in Alpharetta, Georgia. Specializing in the development of pharmacological therapies, the company's primary focus is on treating blinding diseases of the eye through their innovative suprachoroidal space (SCS) technology.

Clearside Biomedical's cornerstone is their SCS Microinjector®, a proprietary device that facilitates a non-surgical, office-based procedure. This technology allows for targeted delivery of therapies directly to the macula, retina, or choroid, which could potentially preserve and enhance vision for patients suffering from severe eye conditions.

One of the company's significant achievements is the robust safety profile and encouraging efficacy data from multiple studies using the SCS Microinjector®. These findings have been featured in numerous oral and poster presentations, highlighting the potential of Clearside’s technology in ophthalmic therapeutics.

Clearside Biomedical continues to advance its pipeline of ophthalmic therapies, collaborating with various partners to bring innovative treatments to market. The company remains committed to improving the quality of life for individuals with vision-threatening diseases through groundbreaking research and development.

Recent Achievements:

  • Clinical data utilizing Clearside’s suprachoroidal delivery technology featured in multiple presentations.
  • Enhanced safety and efficacy data presented, showcasing the utility of the SCS Microinjector®.

Investors and media can reach out to Jenny Kobin and Remy Bernarda for more information at ir@clearsidebio.com or by calling (678) 430-8206.

News

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

Rhea-AI Summary
Clearside Biomedical appoints seasoned biotechnology executive Anthony S. Gibney to its Board of Directors, bringing expertise in business strategy, collaborations, finance, and M&A with recent ophthalmic experience. The appointment aims to enhance Clearside's leadership in delivering therapeutics to the suprachoroidal space, particularly as the company advances towards a potential Phase 3 program for CLS-AX in wet AMD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.85%
Tags
management
-
News

Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary
Clearside Biomedical, Inc. (CLSD) executives to participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference. The event will feature President and CEO George Lasezkay and CMO Victor Chong, discussing the company's innovative therapies for eye diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.39%
Tags
conferences
-
News

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Rhea-AI Summary
Clearside Biomedical, Inc. (CLSD) appoints Dr. Victor Chong as Chief Medical Officer, bringing extensive experience in retinal disease research and clinical development. Dr. Chong's background includes work on various retinal diseases and significant contributions to drug development, notably in wet AMD. His appointment signifies a strategic move for Clearside's suprachoroidal product development, with a focus on the upcoming ODYSSEY Phase 2b wet AMD clinical trial data analysis and Phase 3 program planning.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.77%
Tags
management
News

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
Clearside Biomedical, Inc. reports financial results for Q4 2023, remains on track with Phase 2b ODYSSEY Wet AMD trial, and strengthens capital position through equity offering and licensing agreement. Topline data for the ODYSSEY trial expected in Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
earnings
-
News

Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024

Rhea-AI Summary
Clearside Biomedical, Inc. (CLSD) is set to report its fourth quarter and full year 2023 financial results on March 12, 2024. The company will host a webcast and conference call to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
conferences earnings
-
News

Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering

Rhea-AI Summary
Clearside Biomedical, Inc. announced a registered direct offering of 11,111,111 shares of common stock and accompanying warrants to purchase the same number of shares. The offer price for one share and accompanying warrant is $1.35, with the warrants having an exercise price of $1.62 per share. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
offering
News

Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Rhea-AI Summary
Clearside Biomedical, Inc. (Nasdaq: CLSD) completes randomization in ODYSSEY Phase 2b clinical trial for CLS-AX in neovascular age-related macular degeneration (wet AMD), with topline data expected in Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
Clearside Biomedical, Inc. (Nasdaq: CLSD) expands its proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor through a new licensing partnership with BioCryst Pharmaceuticals. The collaboration includes $5 million upfront and the potential for additional $77.5 million in milestone payments, plus royalties. Recruitment for the CLS-AX Phase 2b ODYSSEY Wet AMD Trial is completed, with topline data expected in Q3 2024. The company's President and CEO, George Lasezkay, highlighted the strategic advancements in the internal pipeline and external collaborations, emphasizing the potential of the partnership with BioCryst to target diabetic macular edema (DME) utilizing suprachoroidal administration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
earnings
-
News

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference

Rhea-AI Summary
Clearside Biomedical, Inc. (CLSD) to participate in fireside chat at Stifel 2023 Healthcare Conference. CEO George Lasezkay to speak on November 15, 2023, at 8:35 a.m. ET in New York, NY. The webcast will be available on the Clearside website under the Investors section.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.65%
Tags
conferences
News

Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting

Rhea-AI Summary
Clearside Biomedical, Inc. (Nasdaq: CLSD) presents encouraging safety and efficacy data at AAO Annual Meeting, highlighting SCS Microinjector's role in treating retinal diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.65%
Tags
clinical trial

FAQ

What is the current stock price of Clearside Biomedical (CLSD)?

The current stock price of Clearside Biomedical (CLSD) is $1.08 as of November 22, 2024.

What is the market cap of Clearside Biomedical (CLSD)?

The market cap of Clearside Biomedical (CLSD) is approximately 80.4M.

What does Clearside Biomedical, Inc. specialize in?

Clearside Biomedical specializes in developing pharmacological therapies for blinding eye diseases using their proprietary SCS Microinjector® technology.

Where is Clearside Biomedical, Inc. located?

Clearside Biomedical, Inc. is located at 1220 Old Alpharetta Rd., Suite 300, Alpharetta, GA, United States.

What is the SCS Microinjector®?

The SCS Microinjector® is Clearside Biomedical's proprietary device designed for non-surgical, targeted delivery of therapies to the macula, retina, or choroid.

How does Clearside Biomedical's technology benefit patients?

Their technology allows for targeted drug delivery to specific parts of the eye, which may help preserve and improve vision in patients with severe eye diseases.

What recent achievements has Clearside Biomedical reported?

Clearside Biomedical has reported a robust safety profile and encouraging efficacy data from studies using the SCS Microinjector®.

Who can be contacted for investor and media inquiries?

For investor and media inquiries, Jenny Kobin and Remy Bernarda can be contacted at ir@clearsidebio.com or (678) 430-8206.

What kind of presentations feature Clearside's technology?

Clearside's suprachoroidal delivery technology has been featured in multiple oral and poster presentations.

What diseases is Clearside Biomedical targeting with their therapies?

Clearside Biomedical is targeting sight-threatening eye diseases with their pharmacological therapies.

Is Clearside Biomedical's procedure surgical?

No, Clearside Biomedical's SCS Microinjector® enables a non-surgical, office-based procedure.

What is the significance of Clearside's technology in ophthalmology?

Clearside's technology offers a potential breakthrough in delivering effective treatments for serious eye conditions, potentially preserving and improving vision.

Stock CLSD logo
Clearside Biomedical, Inc.

Nasdaq:CLSD

CLSD Rankings

#4541 Ranked by Market Cap
N/A Ranked by Dividends

CLSD Stock Data

80.39M
70.22M
7.39%
23.17%
2.35%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
ALPHARETTA